Recombinant Human APG5L/ATG5 Protein

重组人APG5L/ATG5蛋白 | 重组人自噬相关蛋白5

APG 5 | APG 5L | APG5 | APG5 autophagy 5 like | APG5 like | APG5-like | APG5L | Apoptosis specific protein | Apoptosis-specific protein | ASP | ATG 5 | Atg5 | ATG5 autophagy related 5 homolog | ATG5_HUMAN | Autophagy protein 5 | Autophagy related 5 | hAPG

rp184113-10μg

10μg

无载体

≥95%(SDS-PAGE)

Involved in autophagic vesicle formation. Conjugation with ATG12, through a ubiquitin-like conjugating system involving ATG7 as an E1-like activating enzyme and ATG10 as an E2-like conjugating enzyme, is essential for its function. The ATG12-ATG5 conjugate acts as an E3-like enzyme which is required for lipidation of ATG8 family proteins and their association to the vesicle membranes. Involved in mitochondrial quality control after oxidative damage, and in subsequent cellular longevity. The ATG12-ATG5 conjugate also negatively regulates the innate antiviral immune response by blocking the type I IFN production pathway through direct association with RARRES3 and MAVS. Also plays a role in translation or delivery of incoming viral RNA to the translation apparatus. Plays a critical role in multiple aspects of lymphocyte development and is essential for both B and T lymphocyte survival and proliferation. Required for optimal processing and presentation of antigens for MHC II. Involved in the maintenance of axon morphology and membrane structures, as well as in normal adipocyte differentiation. Promotes primary ciliogenesis through removal of OFD1 from centriolar satellites and degradation of IFT20 via the autophagic pathway. May play an important role in the apoptotic process, possibly within the modified cytoskeleton. Its expression is a relatively late event in the apoptotic process, occurring downstream of caspase activity. Plays a crucial role in IFN-gamma-induced autophagic cell death by interacting with FADD. Post-translational: Conjugated to ATG12; which is essential for autophagy, but is not required for association with isolation membrane. Acetylated by EP300.

重组表达

33.3 kDa

N-His

29.8 kDa, under reducing conditions; 29.9 & 61.3 kDa, under non-reducing conditions.

E. coli Accession #: Q9H1Y0 | E. coli

<1.0 EU/μg

人(Human)

2-275 aa

MHHHHHHTDDKDVLRDVWFGRIPTCFTLYQDEITEREAEPYYLLLPRVSYLTLVTDKVKKHFQKVMRQEDISEIWFEYEGTPLKWHYPIGLLFDLLASSSALPWNITVHFKSFPEKDLLHCPSKDAIEAHFMSCMKEADALKHKSQVINEMQKKDHKQLWMGLQNDRFDQFWAINRKLMEYPAEENGFRYIPFRIYQTTTERPFIQKLFRPVAADGQLHTLGDLLKEVCPSAIDPEDGEKKNQVMIHGIEPMLETPLQWLSEHLSYPDNFLHISIIPQPTD​

No

Yes